Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and diagnostic findings in COVID-19 patients: an original research from SG Moscati Hospital in Taranto Italy.
Balzanelli M, Distratis P, Catucci O, Amatulli F, Cefalo A, Lazzaro R, Aityan KS, Dalagni G, Nico A, De Michele A, Mazza E, Tampoia M, D'Errico P, Pricolo G, Prudenzano A, D'Ettorre E, Di Stasi C, Morrone LFP, Nguyen KCD, Pham HV, Inchingolo F, Tomassone D, Gargiulo Isacco C. Balzanelli M, et al. Among authors: de michele a. J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):171-183. doi: 10.23812/20-605-A. J Biol Regul Homeost Agents. 2021. PMID: 33491346
An Alternative "Trojan Horse" Hypothesis for COVID-19: Immune Deficiency of IL-10 and SARS-CoV-2 Biology.
Balzanelli MG, Distratis P, Aityan SK, Amatulli F, Catucci O, Cefalo A, De Michele A, Dipalma G, Inchingolo F, Lazzaro R, Nguyen KCD, Palazzo D, Tampoia M, Pham VH, Santacroce L, Isacco CG. Balzanelli MG, et al. Among authors: de michele a. Endocr Metab Immune Disord Drug Targets. 2022;22(1):1-5. doi: 10.2174/1871530321666210127141945. Endocr Metab Immune Disord Drug Targets. 2022. PMID: 33504318 Review.
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).
DeMichele A, Dueck AC, Hlauschek D, Martin M, Burstein H, Pfeiler G, Zdenkowski N, Wolff A, Bellet-Ezquerra M, Winer E, Balic M, Miller K, Colleoni M, Lake D, Rubovsky G, Cameron D, Balko J, Singer CF, Nowecki Z, Iwata H, Wolmark N, Parraga KA, Rugo H, Steger GG, Traina T, Werutsky G, Czajkowska D, Metzger O, El-Abed S, Theall KP, Lu RD, O'Brien P, Fesl C, Mayer E, Gnant M. DeMichele A, et al. Breast Cancer Res. 2025 Jan 23;27(1):12. doi: 10.1186/s13058-024-01941-3. Breast Cancer Res. 2025. PMID: 39849600 Free PMC article. Clinical Trial.
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
Agostinetto E, Pfeiler G, Hlauschek D, Mayer EL, Lambertini M, de Azambuja E, Bellet-Ezquerra M, Meisel JL, Rubovszky G, Zdenkowski N, Novik Y, Ruiz-Borrego M, Gelmon KA, Mamounas EP, Iwata H, Lu DR, Soelkner L, Fesl C, Gnant M, DeMichele A. Agostinetto E, et al. ESMO Open. 2025 Jan;10(1):104096. doi: 10.1016/j.esmoop.2024.104096. Epub 2025 Jan 3. ESMO Open. 2025. PMID: 39754986 Free PMC article. Clinical Trial.
HER2DX genomic test in early-stage HER2-positive breast cancer.
Tolaney SM, Tung N, Wolff AC, DeMichele A, Cejalvo JM, Martínez-Sáez O, Pascual T, Waks AG, Martín M, Ciruelos E, Harbeck N, Carey LA, Cortés J, Curigliano G, Prat A. Tolaney SM, et al. ESMO Open. 2024 Dec;9(12):103987. doi: 10.1016/j.esmoop.2024.103987. Epub 2024 Nov 16. ESMO Open. 2024. PMID: 39710442 Free PMC article. Review.
A sulfonimide derivative of bezafibrate as a dual inhibitor of cyclooxygenase-2 and PPARα.
Ammazzalorso A, Tacconelli S, Contursi A, Hofling U, Cerchia C, Di Berardino S, De Michele A, Amoroso R, Lavecchia A, Patrignani P. Ammazzalorso A, et al. Among authors: de michele a. Front Pharmacol. 2024 Nov 26;15:1488722. doi: 10.3389/fphar.2024.1488722. eCollection 2024. Front Pharmacol. 2024. PMID: 39660001 Free PMC article.
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Rugo HS, Campbell M, Yau C, Jo Chien A, Wallace AM, Isaacs C, Boughey JC, Han HS, Buxton M, Clennell JL, Asare SM, Steeg K, Wilson A, Singhrao R, Matthews JB, Perlmutter J, Fraser Symmans W, Hylton NM, DeMichele AM, Yee D, Van't Veer LJ, Berry DA, Esserman LJ. Rugo HS, et al. Breast Cancer Res Treat. 2024 Dec 3. doi: 10.1007/s10549-024-07555-9. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39625569
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
Campbell MJ, Wolf DM, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher IR, Zhu Z, Bolen J, Vandenberg S, Hoyt C, Mori H, Borowsky A, Sit L, Perlmutter J, Asare SM; I-SPY2 Investigators; Nanda R, Liu MC, Yee D, DeMichele AM, Hylton NM, Pusztai L, Berry DA, Hirst GL, Petricoin EF, Veer LV, Esserman L. Campbell MJ, et al. Cell Rep Med. 2024 Nov 19;5(11):101799. doi: 10.1016/j.xcrm.2024.101799. Epub 2024 Nov 6. Cell Rep Med. 2024. PMID: 39510069 Free PMC article.
284 results